These are interesting times for H. Lundbeck (OTCPK:HLUYY)
(LUN.CO) and its shareholders. This smallish Danish specialty
pharmaceutical company is attempting to launch new drugs into crowded
markets with questionable differentiation and has a relatively modest
(and high-risk) pipeline, as well as limited resources with which to
acquire new candidates. Amidst these challenges, the company saw its CEO
resign for violating its code of ethics - hardly what investors ever
want to see amidst challenging multi-market drug launches.
Wednesday
may go down as a big turning point. There are still very legitimate
worries about the future of the company's newest launches, but the
company announced the hiring of a very well-regarded pharma executive as
its new CEO. His options may be limited by Lundbeck's resources and
reputation, but investors who are positive on the company's new drugs
and underlying approach to drug development are going to very much look
forward to what he can offer in terms of better sustained performance.
Click this link for the full article:
A New Beginning For Lundbeck, But Not A Clean Start
No comments:
Post a Comment